Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Similar documents
INSULIN 101: When, How and What

Diabetes Head to Toe May 31, 2017

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Guide to Starting and Adjusting Insulin for Type 2 Diabetes*

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Learning Objectives. Are you ready for more insulin formulations?

Update on Insulin-based Agents for T2D

Mixed Insulins Pick Me

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Insulin Prior Authorization with optional Quantity Limit Program Summary

Initiating Injectable Therapy in Type 2 Diabetes

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Comprehensive Diabetes Treatment

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Position Statement of ADA / EASD 2012

Basal Bolus Insulin Therapy Frequently Asked Questions

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

UKPDS: Over Time, Need for Exogenous Insulin Increases

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

LET S TALK INSULIN THE BASICS

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

New Therapies for Diabetes Management: Hope or Headache?

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Insulin Initiation and Intensification. Disclosure. Objectives

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

Converting lantus to humalog 75 25

Starting and Helping People with Type 2 Diabetes on Insulin

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Nph insulin conversion to lantus

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy

Inpatient Glycemic Management:

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Insulin 301: Case, after case, after case

Individualizing Care for Patients with Type 2 Diabetes

Table 1. Antihyperglycemic agents for use in type 2 diabetes

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

Injecting Insulin into Out Patient Practice

Type I Type II Insulin Resistance

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Type 2 Diabetes Mellitus Insulin Therapy 2012

DEMYSTIFYING INSULIN THERAPY

Diana McNeill MD, FACP Professor of Medicine Duke University Medical Center. Disclosures

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Premixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s

These Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP

5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives

4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures

3. Cardiovascular Disease?

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Intensification of Diabetic Therapy. Case studies

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Injectable Therapies in Diabetes

第十五章. Diabetes Mellitus

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

The York Diabetes Care Model

BEST 4 Diabetes. Optimisation of insulin module

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Module 5. Understanding Insulin Therapy

APPENDIX American Diabetes Association. Published online at

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

BEST 4 Diabetes. Optimisation of insulin module

Insulin Therapies: An Educational Toolkit

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Injectable Therapies in Diabetes

Medications for Diabetes

2018 Diabetes Summit Managing Diabetes: An Art and a Science

Insulin Therapy Management. Insulin Therapy

Case Study: Competitive exercise

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk

The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

DIABETES INDICATIONS FOR INSULIN

Insulin for Adults with Type 2 Diabetes

Diabetes Mellitus II CPG

Diabetes, Type 2 Management

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per

Transcription:

Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital

Progression of type 2 diabetes Beta cell apoptosis

Natural History of Type 2 Diabetes

The Burden of Treatment Failure in Type 2 Diabetes Brown JB. Diabetes Care July 2004. 9% 8% 7% Patients spend on average of 59 months on dual oral agents with A1C > 7.0% before insulin is initiated

Physiologic Insulin Secretion

Bottom Line It s Definitely Time to Start Insulin If : Decompensated diabetes i.e. if symptomatic hyperglycemia and losing weight. A1C > 9.5%, FBG > 14 mmol/l, insulin is required. Preconception Type 2 Diabetes.

Decompensated Diabetes +/- Metformin May be short term insulin; 4-6 weeks if turns out to be new T2D. Send GAD Antibodies if age < 40 or lean.

Bottom Line Consider Insulin if : If A1C >8.5% on pharmacologic therapy. Ideally initiate insulin when A1C < 8.5% on oral agents so able to start with fewer injections and simplified regime. If contraindication or intolerances to multiple oral agents limits therapy (i.e. renal insufficiency).

Oral Agents and Insulin Initiation What to Keep and What to Stop Unless contraindicated, Metformin is usually continued to decrease variability of morning glucose and to mitigate weight gain on insulin. May wean other oral agents if doing well on moderate doses of insulin. Secretagogues (i.e. SU s) should be stopped once on meal insulin.

Choices of Insulin Regimes Basal intermediate or basal analog at hs. Basal Plus 1-2 meal doses of rapid insulin. Premix rapid. Basal bolus (MDI).

Basal Insulins: Intermediate Acting Humulin N, Novolin NPH: cloudy due to preservatives that allow prolonged action so half life is 14-18 hours. Less than half the price of basal analogues and no difference in A1C but some increase in nocturnal hypoglycemia. Must mix properly before injection by rolling and rotating pen 20 x or will risk hypoglycemia. 20% coefficient of variation in effect so try to avoid in type 1 diabetes. Vial (1000 units) is $20 or 5 cartridges (1500 units) $8.50 each and $42 for pack of 5. is

Basal Analogues Basalglar (biosimilar glargine, $15 per cartridge), Lantus (glargine, $18.50 per cartridge), Levemir (detemir $20). Smoother 24 hour profile with somewhat less nocturnal hypoglyemia vs. intermediate acting insulin. Clear, so no mixing required and can be given AM or HS. Levemir has a shorter half life so may need BID. More weight favorable but most expensive basal analog.

Rapid Acting Insulins Apidra (glulisine $10 per cartridge), Humalog (lispro, $11 per cartridge), NovoRapid (aspart $12 per cartridge). Often helpful to give 10-15 minutes ac unless glucose <5. Health Canada recent approval of faster insulin aspart, Fiasp. Concentrated insulins

Injection Technique: 4 mm Pen Needles and Site Rotation Leave needle in 10 12 seconds after injection

Injection Technique: Site Rotation

Starting Basal Insulin Not very useful if the AM glucose is the best of the day lean elderly more insulin deficient than resistant). Least weight gain and hypoglycemia vs. other regimes. Usual starting dose is 10 units NPH, N, Lantus, Levemir or Basalglar. Titrate up by 1 unit every night until fasting glucose is 5-6 mmol/l. No further dose increase if 1 nocturnal low or 2 morning lows. Average hs NPH dose (+ daytime Metformin) is 42 units. Average Lantus dose 47 units but 30% require > 60 units. (i.e.

Pitfalls Very high dose glargine (Lantus) 80-100 units and persistent daytime hyperglycemia (? max 0.5 u/kg). Likely needs 1-3 meal doses if glucose falls significantly overnight (BeAM factor > 3 mmol/l). Beware the catecholamine effect of untreated OSA causing increasing overnight glucose. Often can reduce very high Lantus dose 20% -30% and use this amount of insulin for divided meal doses.

Predicting Success of Daytime Oral Agents and Bedtime Insulin Baseline A1C < 8.5% Baseline A1C > 8.5% 75% get to goal 45% get to goal Consider Basal plus One

Insulin Initiation: Multiple Injections Premix Analogs MDI Humalog Mix 25 and Mix 50 and NovaMix 30. Start 6-10 units BID (ac bkft and ac supper) and titrate morning dose based on before supper readings and evening dose based on AM readings. Must have stable meals and activity. No adjustment scale possible. 0.3 0.5 units/kg total daily dose. Use lower range if elderly, lean or renal insufficiency. 40% basal and 20% each meal. Most flexible regime but 4 injections per day. Preferred regime for Type 1 diabetes where starting dose should be 0.5 u/kg.

Meal Insulin Type 2 Diabetes: usually don t need carb counting can often give a range i.e. 10 units for a small meal and 15 units for a large meal. In insulin resistance often helpful to give rapid acting meal dose 15-30 minutes before the meal rather than progressively increase the dose and provoke further weight gain.

Coming Soon: Basal GLP-1 Agonist Combinations Lantus Lixisenatide (LixiLan). Degludec Liraglutide (ideglira). GLP-1 mitigates the weight gain of insulin with excellent A1C lowering effect.

Monday 45 year old woman came to Sackville ER with blurry vision. Polyuria, nocturia and some weight loss over past 3 weeks. Weight 60 kg. Blood glucose 37 mmol/l. What s your management? Start MDI with 0.5 units/kg (30 units/d) with 40% basal i.e. 12 units and remainder divided for meals i.e. 6 units per meal

Wednesday 66 year old male with T2DM on Metformin, Diamicron MR and A1C 9.0%. Weight 102 kg and BMI 39. Doesn t want to gain more weight. Doesn t want low blood sugars. Mild gastroparesis.

Correct Treatment HYPOGLYCEMIA

Trimble LA et al. Can J Diabetes 2005;29(2):102-2013 Elderly on Insulin Mini Cog Clock drawing test can be used to predict who is likely to have problems with insulin therapy Write numbers on the blank clock face and draw hands on the clock to show 10 minutes past 11 o clock

Diabetes in the Elderly 2013 Checklist INDIVIDUALIZE glycemic targets based on the above (A1C 8.5% for frail elderly) but if otherwise healthy, use the same targets as younger people AVOID hypoglycemia in cognitive impairment SELECT antihyperglycemic therapy carefully caution with sulfonylureas or thiazolidinediones Basal analogues instead of NPH or human 30/70 insulin Premixed insulins instead of mixing insulins separately in syringe. GIVE regular diets instead of diabetic diets or nutritional formulas in nursing homes

Diabetes in the frail and not so frail elderly Lean elderly are usually insulin deficient not insulin resistant so basal insulin alone often not very useful. Caution in stopping longstanding insulin C-peptide.

Blood Glucose Meter with Rapid Acting Insulin Calculator (InsuLinx)

Memory Pens for NovoRapid

Libre Glucose Monitor

Summary: Insulin ADVANTAGES Long-term experience No maximal dose Multiple formulations and regimens No contraindications DISADVANTAGES Injection Hypoglycemia risk Weight gain Increased cost of SMBG No increased CV or cancer risk SMBG= Self-monitoring of blood glucose Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2013;37(suppl 1):S1-S212. Origin Trial Investigators. NEJM 2012.;367(4):309-318.

Bottom Line It s Definitely Time to Start Insulin if : Decompensated diabetes i.e. if symptomatic hyperglycemia and losing weight. A1C > 9.5%, FBG > 14 mmol/l, insulin is required. Preconception Type 2 Diabetes.

Starting Basal Insulin Not very useful if the AM glucose is the best of the day (i.e. lean elderly more insulin deficient than resistant). Least weight gain and hypoglycemia vs. other regimes. Usual starting dose is 10 units NPH/N, Lantus, Levemir or Basalglar. Titrate up by 1 unit every night until fasting glucose is 5-6 mmol/l. No further dose increase if 1 nocturnal low or 2 morning lows. Average hs NPH dose (+ daytime Metformin) is 42 units. Average Lantus dose 47 units but 30% require > 60 units.

Pitfalls Very high dose glargine (Lantus) 80-100 units and persistent daytime hyperglycemia (? max effect 0.5 u/kg). Likely needs 1-3 meal doses if glucose falls significantly overnight (BeAM factor > 3 mmol/l). Basal Plus 1. Beware the catecholamine effect of untreated OSA causing increasing overnight glucose. Often can reduce Lantus dose 20% -30% and use this amount of insulin for divided meal doses.

Insulin Initiation: Multiple Injections Premix Analogs MDI Humalog Mix 25 and Mix 50 and NovaMix 30. Start 6-10 units BID (ac bkft and ac supper) and titrate morning dose based on before supper readings and evening dose based on AM readings. Must have stable meals and activity. No adjustment scale possible. Highest rate of weight gain hypoglycemia and least efficacious at A1C lowering. 0.3 0.5 units/kg total daily dose. Use lower range if elderly, lean or renal insufficiency. 40% basal and 20% each meal. Most flexible regime but 4 injections per day. Preferred regime for Type 1 diabetes where starting dose should be 0.5 u/kg.

Meal Insulin Type 2 Diabetes: usually don t need carb counting can often give a range i.e. 10 units for a small meal and 15 units for a large meal. Can start at 6 units per meal but if already on a large dose of basal can often start 0.1 unit/kg/meal (i.e. 90 kg start 9 units per meal) and may reduce basal dose. In insulin resistance often helpful to give rapid acting meal dose 15-30 minutes before the meal rather than progressively increase the dose and provoke further weight gain (unless insulin Fiasp).

Bottom Line Consider Insulin if : If A1C >8.5% on pharmacologic therapy. Ideally initiate insulin when A1C < 8.5% on oral agents so able to start with fewer injections and simplified regime. If contraindications or intolerances to multiple oral agents limits therapy (i.e. renal insufficiency).

Basal Analogues Basalglar (biosimilar glargine, $15 per cartridge), Lantus (glargine, $18.50 per cartridge), Levemir (detemir $20). Smoother 24 hour profile with somewhat less nocturnal hypoglyemia vs. intermediate acting insulin. Clear, so no mixing required and can be given AM or HS. Levemir has a shorter half life so may need BID. More weight favorable but most expensive basal analog. Concentrated U300 glargine (Toujeo) need 14% higher dose.

Rapid Acting Insulins Apidra (glulisine $10 per cartridge), Humalog (lispro, $11 per cartridge), NovoRapid (aspart $12 per cartridge). Often helpful to give 10-15 minutes ac unless glucose <5. Health Canada recent approval of faster insulin aspart, Fiasp. Targeted for type 1 diabetes on MDI. Advantage of faster onset so can give immediately ac or even pc meals. Concentrated insulin Humalog U200 in unique pen.